Iscover

Clopidogrel, the active ingredient in Iscover, is an antiplatelet agent presented as an oral tablet for oral use. It helps prevent atherothrombotic events such as heart attack and stroke in patients at risk. GNH USA supplies Iscover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iscover (clopidogrel) acts on platelet aggregation pathways to reduce thrombotic risk. - Acute coronary syndrome: lowers the chance of recurrent myocardial infarction and cardiovascular death. - Stroke and transient ischemic attack: reduces the risk of subsequent ischemic stroke. - Established coronary artery disease: prevents new heart attacks and related complications.

Clopidogrel may cause a range of adverse reactions.

Common Side Effects: - Minor bruising or bleeding from gums. - Gastrointestinal discomfort or dyspepsia. - Skin rash or itching. - Headache or dizziness. - Diarrhea or nausea.

Serious or Rare Side Effects: - Severe bleeding, including intracranial hemorrhage. - Thrombocytopenia or neutropenia. - Allergic reactions such as angioedema or anaphylaxis. - Liver enzyme elevations. - Rare cases of thrombotic thrombocytopenic purpura (TTP).

Clopidogrel requires careful assessment before use. - Assess bleeding risk: evaluate history of gastrointestinal ulcers or recent surgery. - Monitor hematology: check platelet counts and hemoglobin regularly. - Adjust in renal impairment: consider dose review in severe kidney disease. - Caution in pregnancy: use only if benefits outweigh potential risks. - Avoid concomitant NSAIDs or anticoagulants unless medically indicated. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Clopidogrel interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Proton pump inhibitors (omeprazole, esomeprazole): may reduce clopidogrel activation. - Strong CYP2C19 inhibitors (ticagrelor, fluconazole): can diminish antiplatelet effect. - Non‑steroidal anti‑inflammatory drugs (high‑dose ibuprofen, naproxen): increase bleeding risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): additive anticoagulation, monitor INR or bleeding signs. - Selective serotonin reuptake inhibitors (SSRIs): may enhance bleeding tendency. - Statins (simvastatin, atorvastatin): potential pharmacokinetic interaction, observe for adverse effects.